Multidisciplinary Disease Groups

Multidisciplinary Disease Groups are responsible for:

  • Vetting each new trial for adequate concepts and protocols or the population they serve and verifying it aligns itself with the SKCC's objectives
  • Assessing the availability of adequate resources (both financial and feasibility to conduct), participant availability, and existence of pending and open competing trials
  • Monitoring accrual to open, suspend and close trials in conjunction with the SKCC leadership

For questions about MDGs, please contact the CTO Senior Director at Cynthia.Gifford-Hollingsworth@jefferson.edu

The MDG is the first committee that will review an oncology-related study. Note that retrospective chart reviews and correlative lab trials that will utilize banked blood and tissue that do not require informed consent are exempt from MDG review and approval.

The purpose of the MDG is to prioritize and oversee the operations and management of clinical research being conducted within their specific group. There are 7 designated disease groups, and each of them has their own MDG committee. Each committee has a committee leader and a minimum of one co-leader, as well as an MDG coordinator.

There is a specific timeframe in which protocols need to be submitted to the MDG coordinator, and a specific review process. An approval notification is provided.

Institutional Review Board submission preparation should begin after this committee approval is received.


MDG Committee Disease Subcategories Committee Leader(s) Committee Coordinator
Solid Tumor
  • Brain
  • CNS
Shi
Glass
Jessica Burrell
  • Lung
Axelrod
Evans
Enterprise Wide Breast
  • Breast
Abu-Khalaf
Brill
Lopez
Rita Murphy
Enterprise Wide GTN
  • Cervix
  • Endometrial
  • Pelvic
  • Ovarian
  • Uterine
Shahin
Schilder
Ashley Douglas
Jessica Burrell
GI
  • Colon
  • Gastric / GE
  • Hepatocellular
  • Pancreatic
  • Rectal
  • Sarcoma
Posey
Anné
TBD
GU
  • Bladder
  • Prostate
  • Renal
Trabulsi
Tester
Den
Allison Scott
Head and Neck
  • Head
  • Laryngeal
  • Lips
  • Nasal
  • Oral Cavity
  • Pharyngeal
  • Thoracic
Cognetti
Bar-Ad
Johnson
Camilo Henao
Heme
  • Leukemia
  • Lymphoma
  • MDS
  • Myeloma
Kasner
Porcu
Palmisiano
Ariel Kobylak
IECT
  • BMT
  • GVHD
  • Immune Effector Cellular Therapy
Gergis
Carabasi
Gross
Natisha Muhammad
Melanoma
  • Melanoma
  • Uveal Melanoma
Sato
TBD
Phase 1
  • Phase I trials specifically for all tumor types
Schilder
Dennis Stone
Jefferson Northeast
  • All
Brose (Lead)
Bhatia
Rudoler
Ryan Tingler

Information
MDG Committee Information Info 01/24/2022
MDG Leaders Info 08/17/2017
MDG SOP SOP 04/12/2018
Processing an MDG Approval Guidance 08/19/2016
CTO Contact List by MDG Info 03/04/2019
JeffTrial Staff List for MDG Coordinators Guidance 07/27/2016
JeffTrial Uploading for MDG Coordinators Guidance 07/27/2016
Key Questions for MDC Committee Members Info 08/30/2018


Templates & Forms
MDG Meeting Agenda Template 05/20/2016
MDG Meeting Minutes Template 05/20/2016
MDG Meeting Attendance Sheet Template 05/20/2016
Disease Map Template 05/20/2016
MDG Protocol Portfolio Template 05/20/2016
MDG Participant List Template 05/20/2016
Priority Score Form Form 01/18/2022
MDG New Study Approval E-Mail Template 02/07/2019
MDG New Study Disapproval E-Mail Template 06/06/2016
MDG Committee Protocol Concept Email Template Template 04/13/20018
Annual Report Template In Process
Roster Template Template 06/06/2016